𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

✍ Scribed by Paolo Alberto Paciucci; Janet Cuttner; James F. Holland

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
389 KB
Volume
35
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sequential mitoxantrone, daunorubicin, a
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia
✍ Paciucci, Paolo Alberto; Cuttner, Janet; Gottlieb, Arlan; Davis, Roger B.; Marte πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 27 KB

Mitoxantrone (M) is a synthetic aminoanthraquinone with anti-leukemic activity in patients with daunorubicin (D) resistant acute leukemia. The Cancer and Leukemia Group B (CALGB) has undertaken a limited access pilot study in which M, 12 mg/m2, over 30 min, daily for 3 days, and cytosine arabinoside

Mitoxantrone and high-dose cytosine arab
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 447 KB πŸ‘ 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete

High antileukemic activity of sequential
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias : Results of a clinical Phase II study
✍ Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard WΓΆrmann; Thomas BΓΌ πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 2 views

Department of Heremission whereas 5 patients (23%) succumbed to early death and 3 patients (14%) matology and Oncology, Go Β¨ttingen, Germany. did not respond. Blood counts recovered at a median of 33.5 days after the start 2 Westfa Β¨lische Wilhelms University, Department of treatment and complete r